RevOpsis Therapeutics
RevOpsis
Dover, United States · Founded 2022 · $16.5M raised
- Headquarters
- Dover
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- revopsis.com
- Total Funding
- $16.5M
- Last Round
- $16.5M SeedAug 2023
- Rounds
- 1
About
RevOpsis Therapeutics is a next-generation biopharmaceutical company developing multispecific antibody therapies using its proprietary Rev-Mod Platform. Its lead asset RO-104 is a trispecific biologic targeting retinal vascular diseases including neovascular age-related macular degeneration. Based in Dover, Delaware with 2-10 employees.
Summary
RevOpsis Therapeutics is a Biotechnology company based in Dover, United States, founded in 2022. It has raised $16.5M in total across 1 round, most recently a $16.5M Seed round in Aug 2023.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Aug 2023
Similar Companies
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal ...
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Leading innovative radiopharmaceutical company in China developing next-generation radiopharmaceu...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage biopharmaceutical company developing small-molecule therapies for serious diseases...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/revopsis-therapeutics"><img src="https://indexed.vc/api/badge/company/revopsis-therapeutics" alt="RevOpsis Therapeutics on Indexed.vc" width="260" height="76" /></a>